Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
1(10%)
Results Posted
88%(7 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_4
1
10%
Ph phase_2
5
50%
Ph phase_3
2
20%
Ph phase_1
2
20%

Phase Distribution

2

Early Stage

5

Mid Stage

3

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
5(50.0%)
Phase 3Large-scale testing
2(20.0%)
Phase 4Post-market surveillance
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(1)
Completed(8)
Terminated(1)

Detailed Status

Completed8
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (20.0%)
Phase 25 (50.0%)
Phase 32 (20.0%)
Phase 41 (10.0%)

Trials by Status

terminated110%
completed880%
active_not_recruiting110%

Recent Activity

1 active trials
Showing 5 of 10
active_not_recruitingphase_4

A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration

NCT06970665
completedphase_3

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

NCT05536297
completedphase_2

Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

NCT03364153
completedphase_3

A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

NCT04435366
completedphase_2

Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

NCT02686658
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT06970665Phase 4

A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration

Active Not Recruiting
NCT05536297Phase 3

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

Completed
NCT03364153Phase 2

Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

Completed
NCT04435366Phase 3

A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

Completed
NCT02686658Phase 2

Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Completed
NCT03362190Phase 2

ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)

Completed
NCT02397954Phase 2

A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

Completed
NCT05571267Phase 2

Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD

Terminated
NCT00950638Phase 1

A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration

Completed
NCT00709527Phase 1

ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10